Opko Health Inc. (OPK) - 500 Beiträge pro Seite

[cyba]

hier nun die Fortsetzung des alten "EXEG - Threads"...

Opko Health Inc. (AMEX: OPK) ist aus einem 3 way merger mit der shell EXEG hervorgegangen, alles schön nachzulesen in dem alten EXEG - Thread

Thread: eXegenics Inc. (OTC-BB: EXEG)

[tsylver]

der alte thread ist wohl abgehangen, wie?
zumindest komme ich nicht mehr dort hin...

[tsylver]

die Q2-Zahlen wurden veröffentlicht:

http://investor.opko.com/secfiling.cfm?filingID=950144-07-77…

[tsylver]

Opko Health keine Stücke aus der Hand geben

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten, keine Stücke der Opko Health-Aktie (ISIN US68375N1037/ WKN A0MUUJ) aus der Hand zu geben. Den Experten seien bei Opko Health weitere Insiderkäufe aufgefallen. So hätten im Berichtszeitraum Unternehmensinsider im Gesamtvolumen von mehr als 254.000 USD zwischen Kursen von 3,70 und 4,11 USD weitere Opko Health-Papiere erworben. Die Gesellschaft habe erst Mitte Juli den Beginn abschließender Phase III-Tests von Bevasiranib zur Behandlung von altersbedingter feuchter Makula-Degeneration (AMD) mitgeteilt. Die Forschung an dieser Technologieplattform, auf der das Präparat aufbaue, gelte als potenziell wegweisend und sei schon mit dem Nobelpreis ausgezeichnet worden. Anleger sollen kein Stück der Opko Health-Aktie aus der Hand geben, empfehlen die Experten von "Global Biotech Investing". (Ausgabe 16 vom 20.08.2007) (21.08.2007/ac/a/a)

[tsylver]

Press Release Source: Opko Health Inc.


Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMDThursday August 30, 10:55 am ET
-Groundbreaking Trial Is Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Genentech's Lucentis(R) Administered Every 4 Weeks-


MIAMI, Aug. 30 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that the first patient has been dosed in the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD). The multi- national trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the growth of the abnormal and leaky blood vessels that result in the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility.

"We believe initiation of patient dosing in the COBALT trial is significant both because it is the first-ever Phase 3 trial of an agent based on RNAi gene silencing technology and because the growing population of older people at risk of vision loss from AMD requires therapeutic options that are effective, safe and convenient," said Phillip Frost, M.D., Chairman and CEO of Opko Health. "Our clinical group has already demonstrated its ability to conduct high quality clinical trials rapidly and cost effectively, and we look forward to continued good progress now that patient dosing is underway."

For more information about COBALT bevasiranib clinical sites currently open and enrolling patients, please visit http://www.opko.com/clinicaltrials

About Wet AMD

Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth of abnormal and leaky ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility.

About Opko Health, Inc.

Miami-based Opko is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase 3 trial after successfully completing Phase 2 trials for the treatment of wet age-related macular degeneration and macular degeneration. Opko is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it also intends to market diagnostic systems that complement its therapeutic products. The company recently announced it has entered into an agreement to acquire Ophthalmic Technologies, Inc. (OTI), a provider of innovative patient imaging systems to eye care professionals worldwide.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development efforts, our ability to develop a preclinical pipeline of novel agents for opthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase 3 clinical trial for bevasiranib, may not be successful, that the Phase 3 clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward- looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


Contacts:
GendeLLindheim BioCom Partners
Barbara Lindheim
212 918-4650

Source: Opko Health Inc.

[tsylver]

Frost ups stake in Opko
South Florida Business Journal - 5:50 PM EDT Friday, August 31, 2007by Brian Bandell

Dr. Phillip Frost, Opko chairman and chief executive officer, continued his buying spree of the company's stock on Thursday by acquiring 29,400 shares for a total of $121,302.

Using multiple transactions through his Frost Gamma Investments Trust, the price per share ranged from $4.05 to $4.24. That brought the Miami entrepreneur's holdings in Opko (AMEX: OPK) to about 40.8 million shares.

The transaction capped a busy month of buying for Frost. He acquired about 200,000 shares of Opko in August, Security and Exchange filings show.

In February, Frost, the former head of Ivax Corp., had his private equity group, The Frost Group LLC, pay $8.6 million for 19.4 million shares of eXegenics, for a 51 percent stake, according to its SEC filings. That worked out to about 44 cents a share. He then merged in several private companies and changed its name to Opko.

On July 13, Frost Gamma Investment Trust bought 4.1 million shares of Opko for nearly $7.4 million.

On the scientific front, the Miami-based company announced on Wednesday that it dosed the first patient in its Phase 3 trial of bevasiranib, a treatment of wet age-related macular degeneration.

Opko shares closed down 4 cents to $4.20. The 52-week high was $5.50 on April 16. The 52-week low was 38 cents on Aug. 7, 2006.

[cyba]

Antwort auf Beitrag Nr.: 31.366.567 von tsylver am 02.09.07 02:23:37

immer ein gutes zeichen wenn jemand wie er kauft

[tsylver]

er stockt immer weiter auf. das sollte wohl genug für sein vertrauen in die firma sprechen
aber meine shares bekommt er nicht so günstig

[tsylver]

und Doc Frost kauft weiter:

http://investor.opko.com/secfiling.cfm?filingID=1144204-07-4…

[tsylver]

...und wieder ein neues Form 4 Dokument...

http://investor.opko.com/secfiling.cfm?filingid=1144204-07-4…

[tsylver]

http://investor.opko.com/secfiling.cfm?filingid=1144204-07-4…

und wieder 25k...

[tsylver]

Source: OPKO Health Inc.


OPKO Health to Present at UBS 2007 Global Life Sciences Conference
Tuesday September 18, 8:00 am ET


MIAMI, Sept. 18 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK - News) today announced that it will present at the UBS 2007 Global Life Sciences Conference on Tuesday, September 25, 2007 at 11:30 am EDT. The conference will be held at the Grand Hyatt New York in New York City.

OPKO senior management will provide a review of recent corporate developments.

The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors Relations section of the OPKO Health website at www.opko.com. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation. The live and archived audio webcast can also be accessed at the UBS website at http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20…

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase 3 trial after successfully completing Phase 2 trials for the treatment of wet age-related macular degeneration and macular degeneration. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it also intends to market diagnostic systems that complement its therapeutic products. The company recently announced it has entered into an agreement to acquire Ophthalmic Technologies, Inc. (OTI), a provider of innovative patient imaging systems to eye care professionals worldwide. For more information visit www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development efforts, our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase 3 clinical trial for bevasiranib, may not be successful, that the Phase 3 clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward- looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


Contacts: Media:
Corporate: GendeLLindheim BioCom Partners
Steven D. Rubin Barbara Lindheim
305 575-6015 212 918-4650

Source: OPKO Health Inc.

[cyba]

Antwort auf Beitrag Nr.: 31.648.783 von tsylver am 18.09.07 19:32:47

sollt nen schub geben vielleicht?

[tsylver]

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-5…

...und weiter geht das Einkaufen von Dr. Frost...

[cyba]

Antwort auf Beitrag Nr.: 31.679.990 von tsylver am 20.09.07 20:22:48

[tsylver]

http://investor.opko.com/secfiling.cfm?filingid=1144204-07-5…
http://investor.opko.com/secfiling.cfm?filingid=1144204-07-5…http://investor.opko.com/secfiling.cfm?filingid=1144204-07-5…http://investor.opko.com/secfiling.cfm?filingid=1144204-07-5…
http://investor.opko.com/secfiling.cfm?filingid=1144204-07-5…

[tsylver]

Antwort auf Beitrag Nr.: 31.694.901 von tsylver am 22.09.07 01:17:00

mal nicht Dr. Frost, der ein Form 2 auslöst...

[tsylver]

Antwort auf Beitrag Nr.: 31.694.903 von tsylver am 22.09.07 01:19:33

...Form 4 natürlich...

[cyba]

Antwort auf Beitrag Nr.: 31.694.906 von tsylver am 22.09.07 01:21:15

schon klar

jo die anderen wollen auch was vom kuchen...

[tsylver]

Form 8-K for OPKO HEALTH, INC.

25-Sep-2007

Change in Directors or Principal Officers



ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 25, 2007, Melvin D. Rubin, M.D., resigned as a member of the Board of Directors of OPKO Health, Inc. (the "Company"). The resignation of Dr. Rubin did not involve any disagreement with the Company. In accordance with the Company's bylaws, effective as of September 25, 2007, Pascal J. Goldschmidt, M.D., was appointed as a director of the Company to fill the vacancy created by Dr. Rubin's resignation. Since April 2006, Dr. Goldschmidt, 53, has served as Senior Vice President for Medical Affairs and Dean of the University of Miami Leonard M. Miller School of Medicine. Previously Dr. Goldschmidt was a faculty member with the Department of Medicine at Duke University Medical Center, where he served as Chairman from 2003 to 2006 and as Chief of the Division of Cardiology from 2000 to 2003. Dr. Goldschmidt is a member of the Board of Directors of Pediatrix Medical Group, Inc. It is currently anticipated that Dr. Goldschmidt will be appointed to serve on the Company's Compensation Committee and the Company's Corporate Governance and Nominating Committee. ITEM 8.01. Other Events.

On September 19, 2007, the Company's Board of Directors, upon recommendation of the Compensation Committee, approved certain changes in non-employee director compensation. Previously, non-employee directors received an option to acquire 15,000 shares of the Company's common stock, and the chairman of each of the committees of the Board received an option to acquire an additional 5,000 shares of Company common stock. Effective as of September 19, 2007, (i) each non-employee director is entitled to receive: (a) an annual retainer of $10,000, payable in quarterly installments; and (b) an option to acquire 40,000 shares of the Company's common stock upon initial appointment to the Board and an option to acquire 20,000 shares each year thereafter; and (ii) the chairman of each committee of the Board shall receive $5,000 annually, payable in quarterly installments.

[tsylver]

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-5…

...und es wird weitergekauft...

[tsylver]

Form 3:
http://investor.opko.com/secfiling.cfm?filingid=1181431-07-5…
Form 4:
http://investor.opko.com/secfiling.cfm?filingid=1181431-07-5…

[cyba]

Antwort auf Beitrag Nr.: 31.770.821 von tsylver am 27.09.07 23:49:53

[tsylver]

Antwort auf Beitrag Nr.: 31.757.067 von tsylver am 27.09.07 00:33:38

Thursday, September 27, 2007 - 4:24 PM EDT
UM medical school dean joins Opko's board
South Florida Business Journal - by Brian Bandell

Dr. Pascal Goldschmidt, dean of the University of Miami Miller School of Medicine, joined Opko Health's board of directors on Tuesday.

He replaced the resigning Dr. Melvin Rubin, the chairman emeritus of ophthalmology at the University of Florida.

The ophthalmology drug development company's Securities and Exchange Commission filing said Rubin's resignation did not involve any disagreement with Opko (AMEX: OPK). According to SEC filings, Rubin was awarded a stock option for 20,000 shares at $4.88 each on May 3.

The Miami-based company has licensed technology being developed at UF that could be a treatment for dry age-related macular degeneration. The resignation won't affect its research with the company, Opko Senior VP Steve Rubin said.

"Dr. Rubin has never been the director of a public company," he said. "He made a personal decision that if we didn't need him, he just as soon wouldn't be an active board member."

While Opko will continue working with UF, it will probably expand its relationships with UM and its eye hospital, Steve Rubin said.

Opko's chief executive officer and largest shareholder is Dr. Phillip Frost, a former chairman of UM's board of trustees and a major donor to the university. The former CEO of generic drug maker Ivax Corp. now has UM's top medical executive on board with his new company.

Goldschmidts's specialty is cardiology - which he headed when he worked at Duke University Medical Center - but UM's Bascom Palmer Eye Institute is ranked the top eye hospital in the United States by U.S. News and World Report.

With Opko having recently begun its Phase 3 trial for bevasiranib for the treatment of wet age-related macular degeneration, the input of Goldschmidt and UM could prove useful. Opko also has the services of the Scripps Research Institute President Dr. Richard Lerner, another member of its board of directors.

Opko said Goldschmidt would be appointed to its board's compensation committee and corporate governance committee.

For his services, Goldschmidt will receive an annual retainer of $10,000 in quarterly installments and an option to acquire 40,000 shares of Opko upon initial appointment to the board and an option to acquire 20,000 shares for each year of service.

Goldschmidt is also on the board of directors of Sunrise-based Pediatrix.

[tsylver]

Quelle: http://www.floridatrend.com/article.asp?page=1&aID=94254259.…
b]Eye for Innovation[/b]
Phil Frost was in retirement mode -- then he read about a small Philadelphia company working on gene-silencing drug therapies for eye diseases.
by Mike Vogel

Sam Reich received the cold call of his dreams last year just after the Wall Street Journal published an article about his Philadelphia company’s eye disease therapy. Dr. Phillip Frost, the Miami billionaire who twice struck gold running drug companies, was on the line, inviting Reich to Florida for a meeting.

A year later, Reich’s enterprise is based in Miami, has funding for its final clinical trial and is a key part of Frost’s new publicly traded Opko Health. “I can’t really think of a better outcome for a small company,” says Reich, now Opko’s executive vice president. “What Dr. Frost enabled us to do was the best of all worlds.”
Frost is so taken with Opko that he officially came out of retirement to serve as CEO. Investors are betting that Frost fortunes, like good things, come in threes. “It’s early in the game,” Frost says, deflecting a question about his investor fan following. “My approach is the classical one where the harder I work the luckier I get.”
Frost, 70, began his classical career with a bachelor’s degree in French literature from the University of Pennsylvania. He earned his M.D. from the Albert Einstein College of Medicine in New York before coming to Miami Beach, where he spent nearly 20 years as head of Mount Sinai Medical Center’s dermatology department. In 1972, he began to blossom as one of Florida’s most famed dealmakers. He took over struggling Key Pharmaceuticals, revived it and sold it 14 years later for $800 million to Schering-Plough. He founded generic drug maker Ivax the following year, 1987, and sold it last year for $9 billion to Israel-based Teva Pharmaceutical Industries in what was one of the largest deals, as Florida Trend reported at the time, in Florida history. Forbes places him No. 717 on its list of the world’s richest people with $1.4 billion.
Frost became Teva’s vice chairman and seemed to throttle back. He served on corporate boards as well as the boards of the University of Miami and the Smithsonian Institution. He and his wife, Patricia, are philanthropists. The music school at UM — funded with the $33 million they donated — bears the Frost name.
Frost was looking forward to making passive investments in business ventures that appealed to him. An example: Dreams, a Plantation sports memorabilia and licensed-merchandise company. Frost is a longtime friend of Dr. Richard
Greene, a dermatologist whose son-in-law is Dreams’ CEO, Ross Tannenbaum, and whose son is Dreams’ senior vice president, David Greene. Frost, not a sports collector, took a 14% stake in the company. He counseled Dreams executives to think bigger in an industry with no true national leader. “He’s all about being the 800-pound gorilla,” David Greene says.
Dreams executives long had wanted to move up from the lowly over-the-counter market where Dreams traded to a listing on an exchange. Frost happens to be co-vice chairman of the American Stock Exchange. “In one of our early strategy meetings,” Greene says, “Dr. Frost gets the chairman of the American Stock Exchange on the phone and puts me on the phone with him. It was a pretty fantastic day. It was almost surreal for us.”
Frost took a more active interest in Ladenburg Thalmann, becoming chairman of the old-line but struggling New York investment house. He relocated it to Miami to the former Ivax headquarters building on Biscayne Boulevard that Frost bought from Teva for $18 million.

Ladenburg has developed a specialty in a favorite Frost vehicle for taking companies public — blank-check companies. Rather than go public through an initial public offering of shares, some companies go public by merging with pre-existing public companies that have no line of business. Such empty companies are old firms that either have sold or ceased their operating divisions and now are just publicly traded shells. Or, in the case of blank-check companies, they were founded with no line of business other than to find a private company to merge with and take public.

It’s an inexpensive way for a company to go public, without the vagaries of the IPO market or investment banker valuations. But there’s usually no analyst following and, for investors, it’s a marketplace filled with peril.
Frost used a public shell with $16 million in cash and no business to take the eye therapy company public. Reich had been a graduate student in molecular biology at the University of Pennsylvania’s ophthalmology department in 2002 when he gave up the degree track to co-found privately held Acuity Pharmaceuticals. Acuity is developing gene-silencing drug therapies for eye diseases, most notably wet age-related macular degeneration. Acuity’s drug, bevasiranib, is the first therapy based on a Nobel Prize-winning technique called RNA interference technology to get to phase three clinical trials. Acuity was mulling its options on raising money to fund phase three when Frost called.
The deal Frost cooked up combined Acuity with Froptix, a private Gainesville company using University of Florida-
licensed technology to develop treatments for other eye illnesses, including dry age-related macular degeneration. The two were merged into a public shell and renamed Opko, which trades on the American Stock Exchange.
Opko, with the shell’s cash and a $12-million line of credit from Frost, now has the money for phase three trials, which began in July, and also has Frost’s experience and connections. For instance, Frost sits on the board of La Jolla, Calif.-based Scripps Research Institute and recruited Scripps president and researcher Dr. Richard Lerner as an Opko board member.

Opko has just 32 employees now, but Frost says that in terms of headquarters staff, it could wind up employing more than Ivax did. In March, Opko announced it had agreed to buy Ophthalmic Technologies, a Canadian imaging equipment maker. He also foresees the company going into the dermatology field.
Dermatology and ophthalmology both feature a relatively small number of practitioners, which means Opko won’t need a giant sales and marketing force to reach them. Both are fields ripe for a new era in their science and approaches to care, Frost says.
Wet age-related macular degeneration, the leading cause of vision loss in the developed world, will afflict 11 million people by 2013. Dry age-related macular degeneration afflicts more than 35 million people worldwide.
In therapeutics and diagnostics, “we feel we’re innovators,” Frost says.
So much for downshifting during his golden years. “I was envisioning relaxing a little bit more,” Frost says.

Macular Degeneration
Macular degeneration is caused when part of the retina deteriorates. Early signs of vision loss associated with macular degeneration can include seeing shadowy areas in the central field of vision or experiencing unusually fuzzy or distorted vision. The disease is progressive, with larger areas of the retina affected. As the light-sensitive cells continue to deteriorate, peripheral vision remains, but the ability to clearly see straight ahead is lost.
Source: WebMD, National Eye Institute, National Institutes of Health

[cyba]

Antwort auf Beitrag Nr.: 31.799.376 von tsylver am 30.09.07 23:30:40

[cyba]

OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors
Monday October 1, 2:12 pm ET

MIAMI, Oct. 1 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK - News) has announced the appointment of Pascal J. Goldschmidt, M.D. to its Board of Directors. Dr. Goldschmidt is the Senior Vice President for Medical Affairs and Dean of the University of Miami Leonard M. Miller School of Medicine. Dr. Goldschmidt formerly served as Chairman of the Department of Medicine at Duke University Medical Center.

"We are delighted to welcome an exceptional healthcare leader like Pascal Goldschmidt to our Board," said Phillip Frost, M.D., Chairman and CEO of OPKO Health. "We expect the insight and experience gained from his distinguished record of achievement at several of our most respected academic medical institutions will be very valuable to our efforts to build a successful company dedicated to providing novel diagnostic and therapeutic products to physicians and their patients."

Before assuming his current position, Dr. Goldschmidt was Chief of Cardiology and then promoted to Chairman of the Department of Medicine at Duke University Medical Center. Earlier in his career, Dr. Goldschmidt was Director of Cardiology at The Ohio State University College of Medicine and Public Health, where he built the Heart and Lung Research Institute and a cardiology specialty hospital.

Dr. Goldschmidt serves on the Board of Directors of Pediatrix Medical Group, Inc. He received an M.D. degree from Universite Libre de Bruxelles and completed residency and fellowship training in Belgium at Erasme Academic Hospital and in the United States at The Johns Hopkins University.

Source: OPKO Health Inc.

[tsylver]

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-6…

..und Dr. Frost sammelt weiter ein...

warum geben die Leute ihre shares nur so günstig an ihn ab?

ich warte weiter...

[tsylver]

neues von der Einkaufstour...:

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-6…

[cyba]

Antwort auf Beitrag Nr.: 31.865.333 von tsylver am 06.10.07 12:53:32

die kaufen ja alles weg

[tsylver]

Antwort auf Beitrag Nr.: 31.865.370 von cyba am 06.10.07 12:55:53

wenn die alles kaufen, sehe ich das doch mal als gutes zeichen

langsam aber stetig wird eingesammelt

[cyba]

Antwort auf Beitrag Nr.: 31.866.148 von tsylver am 06.10.07 13:46:26

jo, mach mir hier keine sorgen... die wissen was sie tun

[cyba]

OPKO Health Acquires Rights to Clinical Stage Compound for Dry Eye
Wednesday October 10, 2:25 pm ET

MIAMI, Oct. 10 /PRNewswire-FirstCall/ -- OPKO Health Inc. (Amex: OPK - News) today announced that it has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound with potential utility in the treatment of dry eye.

"Dry eye is an increasingly common condition that can disrupt the lives of those afflicted. It can cause significant discomfort and interfere with vision and everyday activities," said Sam Reich, Executive Vice President of Ophthalmologics at OPKO. "There is only one FDA approved prescription product currently available for dry eye, and we look forward to moving quickly to develop this product as a new and potentially better treatment option."

The compound, civamide, a proprietary TRPV-1 receptor modulator and neuronal calcium channel blocker, is in Phase III clinical trials in an intranasal formulation to treat various types of pain. Increased tear production was observed in over 50% of the patients receiving civamide, and no systemic side effects were noted. Preliminary evidence suggests that civamide's effects on tear production result from its ability to modify signal transduction pathways present in the human lacrimal gland.

"Acquiring rights to this late stage drug candidate reflects our strategy of proactively seeking new products and businesses to help fuel growth at OPKO," said Phillip Frost, M.D., Chairman and CEO of OPKO Health. "This late stage, topically administered compound with demonstrated safety has the potential to reach the market relatively quickly. It addresses a significant unmet need which creates a sizeable opportunity."

Terms of the agreement were not disclosed.

About Dry Eye

Dry eye syndrome is caused by a variety of conditions such as insufficient tear production. It is estimated that 30 to 40 million Americans suffer from the symptoms of dry eyes. Dry eye syndrome is more common with advancing age and the incidence appears to be increasing. Our aging population and the increasing popularity of procedures that can cause dry eye, such as vision- correction surgery and cosmetic eyelid surgery, may be contributing to the increased incidence. Symptoms of dry eye include itching and pain, light sensitivity and stinging. Dry eye patients can experience vision impairment and can have trouble keeping their eyes open for prolonged periods. Current treatments include over-the-counter and prescription eye drops, which can cause irritation, often work only after many weeks of administration and are often ineffective.

Source: OPKO Health Inc.

[tsylver]

und weiter geht die einkaufstour...

neues form 4

http://investor.opko.com/secfiling.cfm?filingID=1181431-07-6…

[tsylver]

Antwort auf Beitrag Nr.: 31.941.314 von tsylver am 11.10.07 16:33:47

...ihr werdet es nicht erraten: dr. frost kauft weitere shares...

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-6…

[tsylver]

Antwort auf Beitrag Nr.: 32.037.900 von tsylver am 17.10.07 00:46:30

http://investor.opko.com/secfiling.cfm?filingID=1181431-07-6…

... und wieder ein Insider-Kauf

Auf jedenfall kommen hier regelmässig News

[cyba]

Antwort auf Beitrag Nr.: 32.102.665 von tsylver am 21.10.07 23:05:47

mal was neues

[tsylver]

Antwort auf Beitrag Nr.: 32.102.684 von cyba am 21.10.07 23:13:55

sieht auch so aus, als ob das so weiter geht...

[cyba]

Antwort auf Beitrag Nr.: 32.102.694 von tsylver am 21.10.07 23:19:31

denke auch

[cyba]

OPKO Health Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections

- Novel Ocular Product Is Specially Designed To Prevent Sight-Destroying Endophthalmitis -

- Rising Number of Invasive Ocular Procedures and Use of Sutureless Ocular Surgery Are Associated With a Higher Incidence of Endophthalmitis -

MIAMI, Oct. 30 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK) today announced that it has acquired exclusive worldwide rights to a novel ocular product for use following invasive retinal procedures to prevent the development of endophthalmitis, a devastating complication that can lead to blindness and loss of the affected eye. The device was invented by two retinal surgeons who serve as clinical advisors to OPKO.

'Experts are raising the alarm about a significant rise in cases of endophthalmitis, a devastating complication of invasive ocular procedures that can result in complete blindness and surgical removal of the infected eye,' said Samuel Reich, Executive Vice President of Ophthalmologics at OPKO. 'We believe this easy-to-use, elegant ocular product can reduce the incidence of endophthalmitis in the significant number of patients at risk annually.'

Experts believe that the incidence of endophthalmitis is growing as a result of the rising number of ocular surgeries being performed, the widespread adoption of sutureless surgical techniques and a significant increase in the number of intravitreal injections. With the advent of injectable therapies such as Lucentis(R) for the treatment of wet age-related macular degeneration (wet AMD), the annual number of injections has risen rapidly. There are estimated to be over 1.5 million invasive retinal procedures, including both surgeries and intravitreal injections, being currently performed in the U.S. alone, and the number is believed to be rising significantly. While most patients suffer no adverse effects from intravitreal injections, all patients who receive invasive retinal procedures are at risk of developing endophthalmitis. There are no products currently available that are specifically designed and optimized for the prevention of endophthalmitis following retinal surgeries and intravitreal injections.

'Endophthalmitis is a complication dreaded by eye care professionals, since its outcome is so devastating for patients,' said Dr. Richard S. Kaiser, M.D., a retinal specialist at the Wills Eye Institute, a co-inventor of this product and an author of a forthcoming paper on the increased incidence of endophthalmitis in the journal Ophthalmology.' Dr. Kaiser's paper showed a greater than 12-fold increase in the likelihood of endophthalmitis when utilizing new sutureless retinal surgery techniques compared to older approaches.

Dr. Kaiser added, 'As practicing retinal surgeons, we designed this collagen-based device specifically for routine use after retinal surgeries and intravitreal injections. We are optimistic that this new product will be effective in helping to reduce the risk of this catastrophic complication among retinal patients.'

Terms of the agreement were not disclosed.

About Endophthalmitis

Endophthalmitis involves inflammation of the intraocular cavities of the eye, usually caused by infection. It typically results as a complication of ocular surgery, intraocular injections or trauma. The injections can expose the eye to potential pathogens and leave behind a needle tract that can also serve as an entrance for a bacterial infection. In addition, retinal surgery is increasingly performed using a new sutureless technique, leaving open wounds to heal over time and potentially exposing the inner structures of the eye to possible infection. Symptoms of endophthalmitis can include pain, redness, lid swelling and decreased visual acuity. Treatment includes antibiotic injections to the infected eye. Despite aggressive therapy, endophthalmitis can be devastating; frequently requiring enucleation, or removal of the infected eye.

SOURCE OPKO Health, Inc.

[tsylver]

http://investor.opko.com/secfiling.cfm?filingID=1181431-07-6…

Dr. Frost kauft weiter

[tsylver]

http://investor.opko.com/secfiling.cfm?filingID=1181431-07-6…

...und weiter...

[tsylver]

http://investor.opko.com/secfiling.cfm?filingID=1144204-07-6…

...und Q3 Zahlen sind auch da...

[cyba]

Antwort auf Beitrag Nr.: 32.431.564 von tsylver am 14.11.07 23:14:28

dankeschön

[tsylver]

http://investor.opko.com/secfiling.cfm?filingID=1181431-07-7…

...und bei diesen Kursen muß er kaufen...

Dr. Frost´s Einkaufstour

[tsylver]

OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc.




MIAMI, Nov 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health Inc. (AMEX: OPK) today announced that it has completed the previously announced acquisition of Ophthalmic Technologies, Inc. (OTI), a privately owned Canadian company providing innovative ocular imaging systems to eye care professionals worldwide.

"OPKO has already made excellent progress in integrating OTI as we have actively worked together over the past months to prepare for the recent market introduction of our breakthrough Spectral SLO OCT system," said Rishard Weitz, President of OTI. "Our team believes there is the potential for powerful synergies between OPKO's therapeutics pipeline and the diagnostic systems and devices used by eye care professionals, and we expect OTI to continue to play an important strategic role in OPKO's plans for a broadly based ophthalmic business."

OTI provides technologically advanced, easy-to-use diagnostic and imaging equipment to the ophthalmology community, marketing a full line of ultrasound and imaging products for both routine and specialized situations. Its new Spectral SLO OCT system is a breakthrough product offering unique advantages over current technology and providing a flexible platform capable of processing a wide variety of diagnostic tests. OTI has a growing distributor network that currently covers more than 40 countries.

Further details of the agreement will be included in the company's 8-K filing with the Securities and Exchange Commission.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases and markets diagnostic systems that complement its therapeutic products. For more information visit the company's website at www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the powerful synergies between our therapeutics pipeline and the diagnostic systems and devices used by eye care professionals, our belief OTI is an excellent strategic foundation for our ophthalmics diagnostics business, our product development efforts, our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, our ability to market diagnostic systems that complement our therapeutic products, as well as other non- historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include an inability to integrate OTI and other acquisitions into OPKO's business, those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts: Media:
Corporate: GendeLLindheim BioCom Partners
Steven D. Rubin Barbara Lindheim
305 575 6000 212 918-4650


SOURCE OPKO Health Inc.


http://www.opko.com

[tsylver]

Antwort auf Beitrag Nr.: 32.618.063 von tsylver am 29.11.07 19:43:01

Form 8-K for OPKO HEALTH, INC.

29-Nov-2007

Entry into a Material Definitive Agreement, Financial Statements and Exhibits



ITEM 1.01. Entry into a Material Definitive Agreement
On November 28, 2007, OPKO Health, Inc., ("the Company") completed the previously announced acquisition of the remaining shares of Ophthalmic Technologies, Inc. (OTI), a privately owned Canadian company providing innovative ocular imaging systems to eye care professionals worldwide. Pursuant to a Share Purchase Agreement and an Exchange and Support Agreement with OTI and its shareholders, the Company exercised an option (the "Option") to acquire the remaining shares of OTI and issued shares exchangeable into an aggregate of approximately 2,817,000 shares of OPKO Common Stock based upon a purchase price of $10,000,000 and a value of $3.55 per share of OPKO common stock.

In April 2007, the Company invested $5 million in OTI in exchange for common shares of OTI equaling one-third of the equity in OTI on a fully diluted basis. The Company also received the Option to purchase the remaining shares of OTI at the time of that investment.

ITEM 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired

The required financial statements for OTI will be filed in accordance with Rule 3-05 of Regulation S-X under cover of Form 8-K/A as soon as practicable, but in no event later than seventy-one (71) days after the date on which this initial report is filed.

(b) Pro Forma Financial Information

The required pro forma financial information for OTI will be filed in accordance with Article 11 of Regulation S-X under cover of Form 8-K/A as soon as practicable, but in no event later than seventy-one (71) days after the date on which this initial report is filed.

(c) Not Applicable

(d) Exhibits

No. Description

99.1 Press Release of the Company dated November 29, 2007

[tsylver]

30.11.2007 | 10:21 Uhr
Thomson Scientific veröffentlicht seine dritte vierteljährliche Ausgabe von Ones to Watch zur Bewertung der vielversprechendsten Arzneimittel in der pharmazeutischen Pipeline
Philadelphia, November 30 (ots/PRNewswire) -

- Novartis führt die Arzneimittelliste mit Exelon TDS zur
Behandlung der Alzheimerschen Krankheit an

Thomson Scientific, Teil von The Thomson Corporation (NYSE: TOC; TSX: TOC) und führender Anbieter von Informations-Lösungskonzepten für die weltweiten Forschungs- und Geschäftsgemeinschaften, hat seinen vierteljährlichen Bericht The Ones-to-Watch veröffentlicht. Dieser bietet Experteneinblicke in die fünf vielversprechendsten Arzneimittel, die zwischen Juli und September 2007 in eine neue Phase der klinischen Entwicklung übergeleitet wurden.

"Die Liste wird dieses Quartal von drei potenziellen Behandlungen für die Alzheimersche Krankheit angeführt. Für zwei dieser Arzneimittel wurden soeben klinische Studien eingeleitet, während die andere bereits die Genehmigung der FDA erhalten hat", sagte Peter Robins, Editorial and Content Manager bei Thomson Scientific. "Der Bericht The Ones to Watch dieses Quartals unterstreicht die laufenden Anstrengungen, Therapien für Krankheiten zu finden, die sich auf alternde und bewegungsarme Bevölkerungen auswirken."

Welches sind die Ones-to-Watch in diesem Quartal?

An der Spitze der Liste dieses Vierteljahres steht Exelon TDS, eine neue perkutane Pflasterrezeptur von Rivastigmin, die sich für Novartis zu einem Gewinner zu entwickeln scheint. In den sieben Jahren seit seiner Einführung hat die orale Rezeptur von ivastigmin
ein jährliches US-Dollar-Wachstum als Behandlung der Alzheimerschen Krankheit und von Demenz im Zusammenhang mit der Parkinsonschen Krankheit verzeichnen können. Die FDA hat Exelon TDS für leichte bis moderate Demenz im Juli 2007 genehmigt. Die Genehmigung der EU erfolgte zwei Monate später. Die Einführung in den USA steht unmittelbar bevor.

Den zweiten Platz der Liste belegt AZOR, das von Daiichi Sankyo für die Behandlung von Hypertonie entwickelt wurde und eine Kombination von zwei Komponentenwirkstoffen umfasst. In früheren Phase-III-Studien erzielten sämtliche Verabreichungsmengen der Kombination grössere mittlere Reduzierungen des Blutdrucks als eines der beiden Arzneimittel alleine. Hierdurch, sowie durch sein
günstiges Nebenwirkungsprofil, sollte AZOR eine attraktive Behandlungsoption für Patienten darstellen, deren Blutdruck nicht auf einen der Wirkstoffe alleine reagiert. Die Genehmigung in den USA erfolgte im September 2007.

Obwohl der Grund für die Menopause auch weiterhin unbekannt ist,
glaubt KV Pharmaceutical, dass EvaMist, das die dritte Position der
Liste einnimmt, Frauen in ihren Wechseljahren erhebliche Vorteile bieten kann. Dieses Produkt ist ein kleiner, leicht zu verwendender
Handapplikator, der eine voreingestellte abgemessene Dosis über die
Haut verabreicht, so dass Estradiol über 24 Stunden hinweg in den Blutstrom abgegeben wird. EvaMist wurde im Juli 2007 von der FDA zugelassen.

Die erste von zwei potenziellen Behandlungsoptionen für Krebs auf der Liste beachtenswerter Arzneimittel, die in diesem Quartal eine Genehmigung erhalten haben, ist Yondelis, das von PharmaMar für Patienten entwickelt wurde, die bei der Behandlung von Weichteilsarkomen nicht auf zuvor durchgeführte Therapien reagiert haben. Yondelis ist das erste genehmigte Produkt von PharmaMar, einem spanischen Biotechnologieunternehmen, das sich auf Krebsarzneimittel konzentriert, die aus Meeresorganismen abgeleitet sind. Das Unternehmen hat sowohl in der EU als auch in den USA "Orphan Drug"-Status, um sich den Schutz gegen generischen Wettbewerb zu sichern.

Die zweite Genehmigung, die Novartis dieses Quartal erzielen konnte, ist für Tasigna, einen oral verfügbaren Hemmstoff für Bcr-Abl, c-Kit, PDGF-R und zugehörige Rezeptortyrosinkinasen für die potenzielle Behandlung diverser Leukämietypen. Das Arzneimittel wurde zwar nur in der Schweiz für chronische myeloische Leukämie genehmigt, die Genehmigung in den USA und Japan wird jedoch erwartet und eine Genehmigung in der EU wurde bereits empfohlen.

Nachstehend die Top fünf Arzneimittel in jeder Kategorie der
Phasenwechsel:

Die fünf vielversprechendsten Arzneimittel für Phase-III-Studien
-- Bevasiranib sodium, (Wet AMD), Opko
-- Rekombinante aktive Glucocerebrosidase, (Morbus Gaucher), Protalix
-- Odanacatib, (Osteoporose), Merck & Co
-- Laquinimod, (multiple Sklerose), Active Biotech/Teva
-- Elesclomol, (solide Tumoren), Synta
Die fünf vielversprechendsten Arzneimittel für Phase-II-Studien
-- CPP-109, (Kokain- und Methamphetaminabhängigkeit), Catalyst
Pharmaceuticals
-- Intranasale Insulinrezeptur, (Diabetes), Nastech
-- LCP-AtorFen, (Cholesterol), Life Cycle
-- EC-145, (Eierstock- und Lungenkrebs), Endocyte
-- TG-100801, (AMD, diabetische makulare Ödeme, diabetische
Retinopathie), TargeGen
Die fünf vielversprechendsten Arzneimittel für Phase-I-Studien
-- Affitope AD-01, (Alzheimersche Krankheit), AFFiRiS
-- MEM-63908, (Alzheimersche Krankheit, Erkrankungen des ZNS),
Memory/Roche
-- TC-5619, (Schizophrenie, Depression), Targacept
-- RDEA-806, (HIV-Infektion), Ardea Biosciences
-- APD-791, (arterielle Thrombose), Arena Pharmaceuticals

Informationen zu diesem Vierteljahresbericht:

Die Daten für diesen Bericht wurden unter Mithilfe von Thomson
Pharma(R), einem umfassenden globalen pharmazeutischen
Informations-Lösungskonzept, welches die gesamte Arzneimittel
Entdeckungs- und Entwicklungs-Pipeline nutzt, analysiert und
zusammengestellt. konkurrenzfähigen Informationen und strategischen
Daten können Entscheidungen begründen und beschleunigen, eine
fokussiertere Zusammenarbeit unterstützen und zu Innovationen
ermutigen.

Für einen Abdruck des vollständigen Berichts mit Analysen besuchen
Sie bitte: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpq
r/tp_qr_jul-sep2007 .pdf. Aufgrund der Länge der URL ist es
empfehlenswert, den Link auszuschneiden und in den Browser zu
kopieren.

Informationen über The Thomson Corporation

The Thomson Corporation (www.thomson.com) ist ein weltweit
führender Anbieter wesentlicher elektronischer Workflow-Lösungen für
Unternehmen und Fachleute. Thomson, mit Geschäftssitz in Stamford im
US-Bundesstaat Connecticut, bietet Experten in den Bereichen Jura,
Steuerwesen, Buchhaltung, Finanzwesen, wissenschaftliche Forschung
und Gesundheitswesen Mehrwert-Informationen, Software-Tools und
Anwendungen. Die Stammaktien des Unternehmens sind an den Börsen in
New York und Toronto notiert (NYSE: TOC; TSX: TOC).

Thomson Scientific ist ein Unternehmen der Thomson Corporation.
Seine Informationslösungen unterstützen Fachleute in allen Stadien
der Forschung und Entwicklung - von der Entdeckung über die Analyse
bis hin zu Produktentwicklung und Vertrieb. Thomson Scientific
Informations-Lösungskonzepte finden Sie unter scientific.thomson.com.

Webseite: http://www.scientific.thomson.com



$story.getcontactHeadline()
Eoin Bedford von Thomson Scientific, [phone],
[e-mail]

[tsylver]

The Frost Group Invests $20 Million in OPKO Health

MIAMI, Dec 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced
that the members of The Frost Group, a private investment group controlled by Dr. Phillip Frost, Chairman and CEO of OPKO
Health, have made a $20 million investment in OPKO. Under the terms of the investment, OPKO will issue 10,869,565 shares of
the Company's common stock, at $1.84 per share, representing an approximately 40% discount to the five-day average trading
price of the stock on the American Stock Exchange. The shares issued in the investment will be restricted securities, subject to
a two year lock- up, and no registration rights have been granted. The Frost Group also includes Dr. Jane Hsiao, Vice
Chairman and Chief Technical Officer of OPKO, Dr. Rao Uppaluri, Chief Financial Officer of OPKO, and Steven D. Rubin,
Executive Vice President-Administration of OPKO.

"We are pleased to make this investment during this important phase of OPKO's product development efforts, with our lead
drug candidate bevasiranib in Phase III trials and the recent launch of our breakthrough diagnostic imaging system," said Phillip
Frost, M.D., Chairman and CEO of OPKO. "This financing transaction shows our continued commitment and confidence in the
success of OPKO and provides OPKO with additional financial resources to support its ongoing efforts to bring its rich pipeline
of novel ophthalmic drugs and products to the market."

The proceeds from the investment will be used to fund research and development efforts, including the ongoing Phase III trial
for bevasiranib and for general working capital. Following this investment, members of the Frost Group will collectively be
deemed to beneficially own in the aggregate approximately 62% of OPKO's outstanding common stock.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular
endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first
therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

Quelle: www.opko.com

[cyba]

OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Thursday December 6, 8:00 am ET

MIAMI, Dec. 6 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today reported that the gene silencing agent bevasiranib, OPKO's lead compound for the treatment of wet age-related macular degeneration (wet AMD), was named one of the top five most promising drugs entering Phase III clinical trials during the third quarter of 2007. The designation was reported in the current issue of The Ones to Watch report issued by Thompson Scientific Inc. Thompson's industry experts stated that their selections this quarter are intended to "showcase the ongoing drive to find therapies for diseases that impact on ageing and sedentary populations." Data for the Thompson report was compiled and analyzed using Thomson Pharma®, a comprehensive global pharmaceutical information solution that covers the entire drug discovery and development pipeline.

"We are very pleased to receive this recognition from Thompson Scientific since we believe bevasiranib has the potential to represent a major advance in the treatment of this common condition that limits the independence and quality of life of millions of older people around the globe," said Phillip Frost, M.D., Chairman and CEO of Opko Health. "Current vision-preserving therapy requires patients with wet AMD to receive intravitreal injections every four weeks, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients, who often have limited mobility. Bevasiranib also has demonstrated excellent safety in clinical trials to date, another important consideration in this patient population."

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

The multi-national Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet AMD is currently enrolling patients at multiple clinical sites. For more information about the COBALT trial, please visit www.opko.com/clinicaltrials

Source: OPKO Health, Inc.

[cyba]

Antwort auf Beitrag Nr.: 32.690.015 von cyba am 06.12.07 21:36:29

wird zeit für mich wieder reinzugehen

[tsylver]

Antwort auf Beitrag Nr.: 32.690.034 von cyba am 06.12.07 21:37:19

nachdem das Board sich schön "bedient" hat, geht es ja jetzt auch wieder aufwärts mit dem Kurs...

[tsylver]

neues form4 document am 10.12.:

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-7…

[tsylver]

Antwort auf Beitrag Nr.: 32.765.341 von tsylver am 14.12.07 14:01:09

ein weiteres form 4 von dr. frost...:

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-7…

[tsylver]

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

NEW YORK, Dec. 18 /PRNewswire/ -- QED International Associates Inc., administrator for the HealthShares(TM) Exchange-Traded Funds, a series of 20 underlying fund portfolios, today announced the quarterly rebalancing of the Indexes.

The following securities will be added and deleted in the Indexes
effective before the opening of trading on NYSE Arca December 24, 2007.


Autoimmune-Inflammation Index (HHA)
Drop Immunomedics, Inc. Nasdaq: IMMU
Add Synta Pharmaceuticals, Inc. Nasdaq: SNTA

Cardiology Devices Index (HHE)
Drop NMT Medical Inc. Nasdaq: NMTI
Add Boston Scientific, Inc. NYSE: BSX

Dermatology and Wound Index (HRW)
Drop Watson Pharmaceuticals Inc. NYSE: WPI
Add Obagi Medical Products, Inc. Nasdaq: OMPI

GI/Gender Index (HHU)
Drop Neurocrine Biosciences, Inc. Nasdaq: NBIX
Add Perrigo Company, Inc. Nasdaq: PRGO

Metabolic-Endocrine Disorders Index (HHM)
Drop Metabais Therapeutics Inc. Nasdaq: MBRX
Add Hospira, Inc. NYSE: HSP

Opthalmology Index (HHZ)

Drop Oxigene Inc. Nasdaq: OXGN
Staar Surgical Co. Nasdaq: STAA
Watson Pharmaceuticals Inc. NYSE: WPI

Add Hi-Tech Pharmacal Co. Inc. Nasdaq: HITK
ISIS Pharmaceuticals Inc. Nasdaq: ISIS
Opko Health, Inc. AMEX: OPK
The rebalanced Indexes, including the rebalanced Index Shares, are
based on the closing prices as of December 17, 2007.

In accordance with the Exemptive Order, a complete list of the
constituents reflecting the rebalancing will be posted at
http://www.healthsharesinc.com/content/view/53/274/." target="_blank" rel="nofollow ugc noopener">http://www.healthsharesinc.com/content/view/53/274/.

About HealthShares(TM)

XShares Advisors LLC, a financial services company based in New York,
is the creator of the HealthShares(TM) family of Exchange Traded Funds
(ETFs). HealthShares(TM) ETFs are organized into therapeutic 'Verticals'
and represent specific areas of the healthcare, life science and
biotechnology industries. Each Vertical addresses a distinct sub-segment of
healthcare, such as the diagnosis and treatment of specific therapeutic
areas (e.g. cardiology, cancer, infectious disease, etc.) and the
development of medical devices (e.g. orthopedic repair, cardio devices,
etc.). Each ETF tracks an index of 22-25 stocks and offers institutional
and individual investors a more precise financial instrument that leverages
the potential of healthcare investing while mitigating the risks of single
stock picking. For more information, visit the company's website at:
http://www.healthsharesinc.com.

About XShares

XShares Advisors LLC, a subsidiary of XShares Group LLC, is a
registered investment advisor that provides investment advisory services to
Exchange Traded Funds. XShares also partners with major institutions and
index providers seeking to bring innovative Exchange Traded Funds to market
using its administrative platform. In addition, XShares creates and
licenses distinctive intellectual property for its ETFs, developing
products that allow for innovative trading strategies and alternative
investments for the financial community. For more information, visit the
company's website at http://www.xsharesadvisors.com.

About QED International Associates

QED International, based in New York, is a leading financial industry
consulting firm specializing in quantitative modeling and the design,
development and maintenance of indexes and Exchange Traded Funds. For more
information, visit the company's website at http://www.qedinternational.com




SOURCE QED International Associates Inc.

[tsylver]

neues form4 von doc frost:

http://investor.opko.com/secfiling.cfm?filingid=1181431-07-7…

[tsylver]

Form Pre 14C / Preliminary Information Statement:

http://investor.opko.com/secfiling.cfm?filingid=950144-07-11…

[cyba]

von mir aus kann es wieder hochgehen

[tsylver]

Antwort auf Beitrag Nr.: 32.882.225 von cyba am 27.12.07 20:12:15

zum ATH sind es 2/3 des jetzigen Kurses. Selbst zum Oktober haben wir rd. 50% Luft nach oben. Bin mal gespannt, wann wir wieder in diese Regionen vorstossen werden.

[cyba]

OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
Monday January 14, 8:00 am ET

MIAMI, Jan. 14 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today announced that Naveed Shams, M.D., Ph.D., has joined OPKO as its Chief Medical Officer and Senior Vice President of Research and Development. Dr. Shams will play a critical role in advancing OPKO's clinical trials and in leading the company's research and development programs.

"Dr. Shams brings 14 years of global drug development experience to OPKO that spans the entire development process, including discovery research, early development, Phase I through Phase IV clinical studies and interaction with regulatory authorities across all stages of R&D," said Phillip Frost, M.D., Chairman and CEO of OPKO. "Dr. Shams will be a tremendous asset to OPKO as we continue to aggressively pursue our research and development programs and advance the clinical testing of bevasiranib, our lead agent for neovascular age-related macular degeneration."

Prior to joining OPKO, Dr. Shams led the clinical team at Genentech, Inc. that developed and launched Lucentis®, an anti-VEGF agent for the treatment of neovascular age-related macular degeneration. His team successfully conducted the SAILOR Study for Lucentis, one of the largest safety studies in the history of ophthalmology, and supported over 50 trials to investigate the safety and efficacy of anti-VEGF treatments in various diseases of the eye.

Previously, Dr. Shams, was a member of the Novartis Ophthalmics Clinical R&D Group, where he led global clinical development and registration efforts for the anti-allergy ophthalmic drug Zaditor® and the intraocular pressure lowering agent Rescula®. He provided post-marketing clinical and regulatory support to Visudyne® for use in patients with age-related macular degeneration. Prior to his position at Novartis, Dr. Shams led the Glaucoma Discovery Group at Storz Ophthalmics, where he helped conduct a trial of cidofovir for the treatment of viral keratoconjunctivitis.

"I am extremely pleased to join OPKO Health at this exciting stage in the development of bevasiranib, a first-in-class drug candidate that has the potential to provide important benefits to patients with age-related macular degeneration," said Dr. Shams. "I look forward to working with OPKO's seasoned management team to further strengthen OPKO's R&D capabilities as it builds its pipeline of drugs for the treatment of ophthalmic diseases."

Dr. Shams received a medical degree from Dow Medical College, Karachi, Pakistan and a doctoral degree in microbiology and immunology from the University of South Carolina. He completed a fellowship in cornea and external disease at the Harvard Medical School and a fellowship in histocompatibility and immunogenetics at Massachusetts General Hospital. Before joining industry, Dr. Shams was a member of the Research Faculty at the Schepen's Eye Research Institute and Department of Ophthalmology at Harvard Medical School.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

The multi-national Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet AMD is currently enrolling patients at multiple clinical sites. For more information about the COBALT trial, please visit www.opko.com/clinicaltrials

Lucentis is a registered trademark of Genentech, Inc. Zaditor, Rescula and Visudyne are registered trademarks of Novartis Pharma.

Source: OPKO Health, Inc.

[tsylver]

Form 8-K for OPKO HEALTH, INC.


15-Jan-2008

Termination of a Material Definitive Agreement, Financial Statements and Exhibi


ITEM 1.02. Termination of a Material Definitive Agreement
On January 11, 2008, OPKO Health, Inc. (the "Company") repaid in full all outstanding amounts and terminated all of the Company's commitments under its $4.0 million term loan with Horizon Financial Funding Company, LLC (the "Loan Agreement"), which was being paid monthly since August 2007 and was to be paid in full by August 2008. The total amount repaid by the Company in satisfaction of its obligations under the Loan Agreement was $2.1 million. The Company realized a net savings by avoiding future interest charges over the remaining term of the obligation, including an immaterial early termination penalty incurred in connection with terminating the Loan Agreement.

ITEM 9.01. Financial Statements and Exhibits.
(a) Not Applicable

(b) Not Applicable

(c) Not Applicable

(d) None

[tsylver]

Antwort auf Beitrag Nr.: 33.076.307 von tsylver am 16.01.08 23:57:12

das liest sich ja sehr positiv!
wenn man einen Kredit schon eher zurückzahlt, muss ja wohl einiges in der Kasse sein...

[tsylver]

Jan 16, 2008

OCT market set for rapid growth
The optical coherence tomography (OCT) market looks poised for continued growth, with revenues expected to top $800 million by 2012. That's the conclusion of a new market research report, Optical Coherence Tomography - Technology, Markets and Applications: 2008-2012. The report, published by US media company PennWell (Tulsa, OK), estimates that the global market for OCT systems currently stands at around $200 million and is growing at an annual rate of 34%.

OCT is a non-invasive optical imaging technique that's becoming an increasingly popular tool in the field of disease diagnostics. First commercialized for medical imaging in 1996, the technique offers the promise of fast, high-resolution diagnostic images for a variety of clinical applications.

According to the market report, OCT's first commercial application - ophthalmology - will continue to dominate through to 2012. However, new applications and products are emerging in areas such as cardiology, dentistry, cancer detection, glucose monitoring and dermatology. In particular, commercial activity for OCT in intravascular imaging has gained momentum over the past 12 months, and this sector looks set to become the next growth market for OCT technologies.

Much of this activity is driven by a shift from time-domain to Fourier-domain OCT technology. While similar in theory and design, Fourier-domain systems offer twice the resolution and 50-100 times the image-acquisition speed. In addition, because the Fourier-domain technique is not protected under the original patents (which limited competition with time-domain systems), there are now several companies developing or marketing Fourier-domain OCT products.

"In 2006, a number of companies introduced 'spectral domain' systems to the ophthalmic market," explained the report's author Greg Smolka. "These offer not only much faster image capture but, more importantly, much higher image accuracy. The new spectral-domain instruments generated a lot of buzz at the 2007 American Academy of Ophthalmology meeting and many see them becoming the dominant imaging system in ophthalmology."

There are at least 18 companies actively developing and/or manufacturing OCT systems. Those profiled in the report include Bioptigen, Carl Zeiss Meditec, Fox Hollow, GlucoLight, Heidelberg Engineering, OPKO, Optopol, Optovue, Topcon Medical Systems, Imalux, ISIS Optronics, Lantis Laser, Lightlab Imaging, Michelson Diagnostics, Santec, Thorlabs, Tomophase and Volcano/CardioSpectra.

In addition, as OCT continues to penetrate new markets, opportunities exist for photonics companies supplying optical sources, detectors and delivery systems. Source and components providers profiled include Cambridge Technology, Denselight, Exalos, Femtolasers, Goodrich, Inphenix, Micron Optics, Multiwave Photonics, NP Photonics, Optiphase and Superlum.

Optical Coherence Tomography - Technology, Markets and Applications: 2008-2012 is available to purchase next month, in print ($4500) and electronic ($4995) form. For more information, see www.bioopticsworld.com.

• Michelson Diagnostics of the UK has this week announced successful results from initial clinical testing of its OCT imaging technology on oral cancer tissue. Scientists at University College Hospital (UCH) in London used Michelson's OCT system to scan 25 cancerous and suspected-cancerous human oral tissue samples. They then compared the OCT images with corresponding histopathology images analysed by trained pathologists.

The results showed that OCT can identify surface structures, such as keratin and epithelial layers, the epidermal/dermal junction and areas of cellular crowding, as well as any pathological changes that occurs at that level. "We are very excited about the breakthrough in image quality that this system offers," said Colin Hopper, senior maxillofacial surgeon at UCH. "OCT could revolutionize the surveillance of pre-cancers in the mouth and eliminate the waiting time for biopsy results."

Further reading
The optical biopsy: coming into view?
Special report: OCT branches out
OCT moves beyond the tipping point
Spectral-domain OCT: faster, more precise

[tsylver]

OPKO Health to Present at 2008 Wachovia Healthcare Conference

MIAMI, Jan 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that it will present at the 2008 Wachovia Healthcare Conference on Wednesday, January 30, 2008 at 11:15 am EST. The conference will be held at the Langham Hotel in Boston.

OPKO senior management will provide a review of recent corporate developments.

A live audio webcast and replay of the company's presentation will be available at the Investor Relations section of the company's website at www.opko.com.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at www.opko.com.

Contacts: Media:
Corporate: GendeLLindheim BioCom Partners
Steven D. Rubin Barbara Lindheim
305 575-6000 212 918-4650


SOURCE OPKO Health, Inc.


http://www.opko.com

[tsylver]

OPKO Health Announces Changes to Board of Directors

MIAMI, Jan 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced the appointment of Thomas E. Beier and Richard C. Pfenniger, Jr. to its Board of Directors. The company also announced the resignation of former Board member David Eichler. Mr. Pfenniger was appointed to fill the vacancy created by Mr. Eichler's resignation while Mr. Beier is assuming a newly created Board position.

"The addition of Tom Beier and Rick Pfenniger to OPKO's Board of Directors ensures the company will continue to benefit from a knowledgeable board with diverse perspectives and experience," said Phillip Frost, M.D., Chairman and CEO of OPKO. "I look forward to working with Tom and Rick and the entire Board of Directors as we continue to aggressively pursue our research and development programs and advance the clinical testing of bevasiranib, our lead agent for age-related macular degeneration. We also want to thank Dave Eichler for his past contributions as a Board member of OPKO."

Richard C. Pfenniger, Jr. joins the Board as Chairman of OPKO's Audit Committee. Mr. Pfenniger currently serves as the Chairman, CEO and President of Continucare Corporation, a provider of primary physician and practice management services. Prior to Continucare, Mr. Pfenniger was CEO and Vice Chairman of Whitman Education Group, Inc. Previously, he was a Director of IVAX Corporation. Mr. Pfenniger currently is a Director of two other companies.

Thomas E. Beier will serve on OPKO's Audit and Compensation Committees. Mr. Beier currently is a Director of Ideation Acquisition Corp., a special purpose acquisition company formed for the purpose of acquiring businesses in digital media. Previously, he was Senior Vice President of Finance and Chief Financial Officer of IVAX Corporation. Before joining IVAX, Mr. Beier served as Executive Vice President and Chief Financial Officer of Intercontinental Bank.

OPKO's Board of Directors now includes ten members.

[tsylver]

in den letzten beiden Wochen kamen rund 3mio weitere Aktien aufs Konto von Doc Frost.

Der Mann kauft weiter...

http://investor.opko.com/sec.cfm

[cyba]

Antwort auf Beitrag Nr.: 33.362.003 von tsylver am 14.02.08 00:35:03

ohne grund wird er dies bestimmt nicht tun

[tsylver]

wenn man schaut, wieviel doc frost von der firma schon besitzt, kann die zukunft nur gut werden.

leider lässt der kursverlauf zu wünschen übrig.
allerdings ist das ein grund um günstig nachzukaufen

[cyba]

Antwort auf Beitrag Nr.: 33.374.977 von tsylver am 14.02.08 22:31:51

jo er hat einen anderen zeithorizont denk ich mal als der "gemeine shareholder" von daher...

[tsylver]

The Success of RNAi Therapeutics Rests On the Development of Technologies That Can Deliver These Agents to Their Targets
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c83496)" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/c83496) has announced the addition of new Decision Resources report Realizing the Promise of Therapeutic RNAi: Emerging Strategies for RNAi Delivery to their offering.

Introduction

The discovery of RNA interference (RNAi) has renewed interest in developing nucleic acid drugs based on targeting messenger RNAs (mRNAs). This field of research offers the potential to produce low-dose, nontoxic RNAi agents to treat important diseases. Venture capitalists have invested large sums of money in RNAi companies, and Big Pharma is acquiring and partnering with RNAi specialty companies. The success of RNAi therapeutics rests on the development of technologies that can deliver these agents to their targets.

Questions Answered in This Report:

- Several companies are focusing on RNAi-based therapeutics. Which are the leading companies in the field, and which ones are in partnership with or have been acquired by Big Pharma? What projects are they undertaking?

- The holy grail for RNAi drug companies remains systemic delivery. Companies are competing furiously to develop viable systemic delivery methods. What are the promising technologies for systemic delivery, and which companies are at the forefront of delivery technology?

- Opko Health's bevasiranib is the most advanced RNAi therapeutic. It is in Phase III clinical trials for wet age-related macular degeneration. What other RNAi therapeutics have been developed and for what disease(s)? At what stage of development are they?

Scope:

- SRNAi: Its mechanism of action.

- Delivery of RNAi therapeutics: Direct delivery of naked siRNA, systemic delivery of siRNA using stable nucleic acid lipid particles (SNALPs), lipidoid nanoparticles, siRNA-lipoplexes, interfering nanoparticles, TargeTran nanoparticles, covalent conjugation of siRNA to a targeting molecule, antibody - mediated targeting of siRNAs, systemic targeting of siRNAs to the CNS.

- Top companies in RNAi research: Alnylam Pharmaceuticals, Sirna Therapeutics, RXi Pharmaceuticals, Silence Therapeutics.

Content Titles Include:

Introduction

Mechanism of RNA Interference

Design of RNAi Research Reagents and Therapeutics

Delivery of RNAi Therapeutics

Alnylam's Direct Delivery of Naked siRNA

Nastech Pharmaceutical's Carrier-Mediated Technology

Systemic Delivery of siRNA Using SNALPs

Alnylam Pharmaceuticals

Sirna Therapeutics

Intellectual Property Issues

Alnylam Pharmaceuticals/MIT's Lipidoid Nanoparticles

Alnylam's Clinical Progress

Silence Therapeutics' siRNA-Lipoplexes

RXi's Interfering Nanoparticles

Intradigm's TargeTran Nanoparticles

Covalent Conjugation of siRNA to a Targeting Molecule

Alnylam Pharmaceuticals

Duke University

Antibody-Mediated Targeting of siRNAs

Systemic Targeting of siRNAs to the Central Nervous System

Company Highlights

Alnylam Pharmaceuticals

Sirna Therapeutics

RXi Pharmaceuticals

Silence Therapeutics

Outlook for the Delivery of RNAi Therapeutics

SPECTRUM Drug Discovery and Design 1-3

RNAi Therapeutics Delivery

Tables

1. Select RNAi Therapeutics in Development

2. Select Technologies for Systemic Delivery of siRNAs

3. Select Companies Developing RNAi Therapeutics and/or Delivery Technologies

Figures

1. Mechanism of RNA Interference

2. Structure of a Stable Nucleic Acid Lipid Particle (SNALP)

3. Schematic of Intradigm's TargeTran Nanoparticles

4. Delivery of siRNAs to Neurons via the Acetylcholine Receptor

Companies Mentioned:

- Acuity Pharmaceuticals

- Alnylam Pharmaceuticals

- Atugen

- CBR Institute for Biomedical Research

- CytRx

- Duke University

- Exegenics

- Eyetech

- Froptix

- Harvard Medical School

- Inex Pharmaceuticals

- Intradigm

- Invitrogen

- Isis

- Medtronic

- Merck

- MIT

- Nastech Pharmaceutical

- Novartis Ophthalmics

- Opko Health

- OSI

- Pfizer

- Protiva Biotherapeutics

- RXi Pharmaceuticals

- Silence Therapeutics

- Sirna Therapeutics

- Tekmira Pharmaceuticals

- University of Massachusetts Medical School

For more information visit http://www.researchandmarkets.com/reports/c83496

Research and Markets Laura Wood Senior Manager Fax: [phone] [e-mail]

Source: http://www.centredaily.com/business/technology/story/415315.…

[tsylver]

OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection

-In Vitro Data Shows OPKO's Formulation of NCT Has Promising Activity Against Acanthamoeba Keratitis, a Serious Ocular Infection-
-Provides Additional Evidence That This Phase II Agent Has Good Tolerability and Broad Anti-Microbial Activity Against a Wide Range of Pathogens-


MIAMI and HINGHAM, Mass., Feb 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) and Pathogenics, Inc. (PTGN.PK) today announced the publication of preclinical data demonstrating the potential therapeutic utility of their proprietary formulation of N-Chlorotaurine (NCT) in the treatment of Acanthamoeba keratitis (AK), a serious eye infection that can result in vision impairment or blindness. AK, which in its ocular form most commonly infects contact lens wearers, is caused by a microscopic amoeba parasite that is present in water, soil and air. Current treatments for ocular AK are potentially toxic and difficult-to-handle. The study was published in the current edition of Antimicrobial Agents and Chemotherapy.*

Led by Dr. Ursula Furnkranz of the Clinical Institute of Hygiene and Medical Microbiology, Medical University of Vienna, Austria, the study authors assessed NCT's microbicidal effect on different strains of the parasite Acanthamoeba, including both the free-living and difficult-to-treat cystic form. The authors showed that, in vitro, NCT clearly demonstrated amoebicidal activity at concentrations that are likely to be well tolerated in humans. They also reported that co-treatment with ammonium chloride appeared to further enhance NCT's anti-parasitic activity, including its activity against Acanthamoeba cysts, resulting in the complete loss of viability of the infection-causing parasites. The authors concluded that NCT might be useful as a topical drug for the treatment of AK infections.

NCT is a derivative of a naturally occurring substance in the body with broad anti-microbial properties. OPKO has in-licensed exclusive worldwide development and commercialization rights to a proprietary formulation of NCT for ocular uses from Pathogenics, Inc. OPKO is currently developing NCT for the treatment of viral conjunctivitis, while Pathogenics is assessing NCT in Phase II studies for topical and body cavity infections.

"These encouraging new data provide further evidence of the safety and anti-microbial efficacy of ACU-NCT-001, OPKO's formulation of N-Chlorotaurine," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "If the broad spectrum activity of NCT continues to be confirmed in clinical trials, its combination of tolerability and anti-infective efficacy could make it a potentially valuable new agent for addressing a variety of ocular infections."

NCT has been shown to have promising anti-microbial activity against bacteria, yeasts and molds, as well as antiviral activity against a number of viruses. To date, NCT has been shown to be safe and well tolerated in multiple applications, including sinus and ear infections, as well as in viral conjunctivitis, or pink eye. Its natural sterility and absence of preservatives make NCT especially well-suited for ocular applications.

About Acanthamoeba keratitis (AK)

Acanthamoeba keratitis is an infection of the transparent outer covering of the eye, or the cornea, caused by a microscopic, free-living amoeba. Acanthamoeba is commonly found in water, soil and air. AK infection is uncommon in healthy individuals, but contact lens wearers who improperly store or disinfect their lenses or who wear lenses while showering or swimming are at higher risk of developing an infection. Current treatment regimens can last a year or more and include a combination of prescription eye medications. Severe vision impairment or loss of the eye may occur, even if the condition is diagnosed early and managed appropriately.

* "Cytotoxic Activity of N-Chlorotaurine on Acanthamoeba spp," Antimicrobial Agents and Chemotherapy. (Furnkranz, U et al. Antimocrob. Agents Chemother.2008;52:470-476).

About Pathogenics, Inc.

Pathogenics, Inc. (PTGN.PK) is a biopharmaceutical company focused on developing its proprietary formulations of N-Chlorotaurine (NCT) for the treatment or prevention of infections. After NCT kills a pathogen, the agent quickly breaks down into natural substances already found in the human body, and therefore it is likely to be extremely safe, non-toxic and hypoallergenic. Unlike antibiotics, the way NCT kills pathogens prevents development of drug resistance. NCT has successfully completed Phase II studies for several topical and body cavity infections. For more information, visit the company's website at http://www.pathogenics.com

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a pipeline of novel agents for ophthalmic diseases and markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at http://www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential utility and benefits of NCT in treating serious ocular infections, and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases and to develop NCT as a treatment for viral conjunctivitis, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib and NCT, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward- looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacts:

OPKO Corporate: Pathogenics, Inc. OPKO Media:
Steven D. Rubin Fred Zotos GendeLLindheim BioCom Partners
305 575-6000 781 556-1090 Barbara Lindheim
212 918-4650

SOURCE OPKO Health, Inc.

http://www.opko.com

[tsylver]

OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

-Second Issued Patent for Bevasiranib Broadly Covers siRNA Targeting of VEGF Expression, Further Strengthening OPKO's RNAi Intellectual Property Portfolio-


MIAMI, March 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (Amex: OPK) today announced that it has been issued a key patent by the United States Patent and Trademark Office (USPTO) for methods related to the use and administration of small interfering RNAs (siRNAs) for targeting vascular endothelial growth factor (VEGF), including OPKO's siRNA drug candidate, bevasiranib, which is currently in a Phase III trial for the treatment of wet age-related macular degeneration (AMD).

The claims of the newly issued patent cover a broad range of methods for the use of a specific sequence of siRNA, including bevasiranib, to target VEGF. The patent also covers application of this specific sequence of siRNA to inhibit the expression of VEGF and to treat VEGF-related angiogenic disorders including age-related macular degeneration, diabetic retinopathy and cancer. In addition, the claims cover any methods of administering the siRNA, including intravenous administration, retinal injections and oral administration. This newly issued patent broadly protecting the applications of OPKO's siRNA bevasiranib is the second for the compound. In late 2006, the USPTO issued a patent covering bevasiranib's composition of matter.

"This patent marks another important step in establishing OPKO's leadership position in the promising field of siRNA-based therapeutics," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "Bevasiranib was the first siRNA to enter human trials, the first siRNA to demonstrate clinically relevant activity in patients, the first siRNA to enter a Phase III pivotal trial and now, one of the first siRNAs to receive a U.S. patent covering its broad therapeutic use. This second issued patent covering bevasiranib and its anti-VEGF applications further reinforces our confidence in our strong and growing intellectual property position in this important space. "

The newly issued patent is exclusively licensed to OPKO on a worldwide basis through an agreement with the University of Pennsylvania.

Bevasiranib is a first-in-class siRNA drug designed to silence the genes that produce vascular endothelial growth factor, believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

The multi-national Phase III COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet AMD is currently enrolling patients at multiple clinical sites. For more information about the COBALT trial, please visit www.opko.com/clinicaltrials.

[cyba]

wieso ist die auf 2$?

hab grad vor schreck nen paar gekauft...
gibts nen grund? hab die letzte zeit die geschichte nicht mehr so wirklich verfolgt

[tsylver]

Antwort auf Beitrag Nr.: 33.767.446 von cyba am 31.03.08 16:12:35

die gehen schon seit dem Herbst kontinuierlich bergab.
scheint auch niemanden zu interessieren, das Doc Frost ebenso kontinuierlich weiterkauft...


http://investor.opko.com/secfiling.cfm?filingID=1144204-08-1…

Form 10-K
Annual Report
Filed Mar 31, 2008

[cyba]

Opko reports first revenue
Wednesday, April 2, 2008 - 4:26 PM EDT

Opko Health said it lost $268.41 million in 2007, but posted revenue for the first time.

The Miami-based developmental-stage health care company was formed as eXegenics, a public shell company, on June 23, 2006. Opko was created via a three-way merger of eXegenics with private companies Acuity Pharmaceuticals and Froptix. It began trading on the American Stock Exchange in June 2007.

Opko (AMEX: OPK) said it lost $268.41 million, or $2.09 a share, on revenue of $847,000 in 2007. In the part of 2006 it was operating, it lost $877,000, or a penny a share, on no revenue.

For the quarter ended Dec. 31, the company lost $9.03 million, or 5 cents a share, on revenue of $847,000. In the prior-year quarter, it lost $620,000, or a penny a share, on no revenue.

In November, Opko bought Ophthalmic Technologies, entering the ophthalmic instrumentation market and generating revenue.

At the end of the year, it said, it had $39.57 million in assets, compared to $116,000 at the end of 2006. It also had 128.77 million outstanding shares, compared with 58.73 million at the end of 2006.

Shares closed down 13 cents to $2.06. No 52-week high/low information was available.

http://southflorida.bizjournals.com/southflorida/stories/200…

[cyba]

OPKO Health Acquires Company Developing Novel Glaucoma Therapy
Wednesday May 7, 7:45 am ET

-Vidus Ocular's Innovative Aquashunt(TM) Device Offers Potential Advantages-
-Glaucoma Affects 2.4 Million Americans and 60 Million People Worldwide-

MIAMI, May 7 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today announced that it has acquired Vidus Ocular, Inc., a privately held company that is developing Aquashunt(TM), an innovative shunt to treat glaucoma, the second leading cause of blindness in the U.S., in an all-stock transaction. Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments. Glaucoma is presently treated with drugs, lasers and surgery, but each has limitations, including efficacy, safety and cost issues.

The patented Aquashunt device was designed by Dr. Bruce Shields, Chairman Emeritus of the Department of Ophthalmology and Visual Sciences at the Yale University School of Medicine. Aquashunt is a simple but elegant approach that uses biocompatible materials and is designed for rapid, simple, minimally traumatic insertion. Aquashunt is intended to reduce intraocular pressure physiologically by allowing excess fluid in the eye to exit naturally. It currently is in preclinical testing and human studies are expected to begin during the fourth quarter of this year.

"Aquashunt is designed to offer a new therapeutic option with significant benefits compared to current therapies," said Dr. Naveed Shams, Chief Medical Officer and Senior Vice President of Research and Development of OPKO. "As a device, it also has the potential for a relatively rapid and straightforward development and regulatory pathway. We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business, providing us with the potential to market an innovative product that addresses a serious disease affecting millions of people."

Glaucoma occurs when fluid accumulating in the eye raises the intraocular pressure and causes the optic nerve to degenerate, potentially leading to irreversible vision loss. Glaucoma is increasing in prevalence as the population ages, currently affecting an estimated 2.4 million people in the U.S. and about 60 million people worldwide.

"We designed Aquashunt with the goal of translating our extensive experience in treating glaucoma into a new type of therapy that would leverage physiologic principles to treat patients more safely, effectively and economically," said Dr. Shields, Chief Scientific and Medical Officer of Vidus Ocular. "Preclinical data on the device are encouraging, and we believe that OPKO is an ideal partner to assume responsibility for the development and commercialization of this potentially important product."

Glaucoma is a significant worldwide health problem affecting patients globally. According to the terms of the agreement, OPKO will also work with Yale University on a number of initiatives to increase access to the Vidus shunt technology in the developing world.

Source: OPKO Health, Inc.

[tsylver]

Antwort auf Beitrag Nr.: 34.059.066 von cyba am 08.05.08 19:44:59

und so wird die company immer weiter ausgebaut...

[cyba]

Antwort auf Beitrag Nr.: 34.060.709 von tsylver am 08.05.08 23:28:02

yup, keine bedenken bis jetzt

[tsylver]

Antwort auf Beitrag Nr.: 34.060.719 von cyba am 08.05.08 23:30:57

All Executive Officers und Directors halten 59% der shares,
wobei Doc Frost ja bald täglich weitere einsammelt...
Johnson & Johnson hält 8,4%

macht zusammen mehr als 2/3.

Alle zusammen haben wohl großes Vertrauen...

[cyba]

Antwort auf Beitrag Nr.: 34.060.771 von tsylver am 08.05.08 23:39:23

denke ich auch

[cyba]

interessant ist auch das dass ganze in einer "in an all-stock transaction" passiert...
lässt darauf schliessen das die verkäufer auch grosses vertrauen in OPK haben!

[cyba]

sieht gut aus, auch vom chart her

[cyba]

Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Tuesday June 3, 11:51 am ET

- Study Published in Journal Molecular Vision -
- Results Show Good Distribution of Bevasiranib to Retina and RPE Cells after a Single Intravitreal Injection -

MIAMI, June 3 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK - News) today announced that a study published in the peer-reviewed journal Molecular Vision demonstrates that bevasiranib, its siRNA (small interfering RNA) agent is distributed throughout the eye, including extensive uptake into the retina. In two tissue distribution and pharmacokinetic studies in rabbits, results showed that bevasiranib was present in the retina and in targeted retinal pigment epithelium (RPE) cells following intravitreal injection. Bevasiranib is a gene-silencing agent designed to shut down the production of vascular endothelial growth factor (VEGF), a primary cause of the new blood vessel growth, or neovascularization, associated with vision loss in patients with wet age-related macular degeneration, or wet AMD. The efficacy and safety of bevasiranib are currently being assessed in the COBALT study, an international Phase III trial for the treatment of wet AMD.

"Importantly, these data indicate that following intravitreal injection, bevasiranib distributes to the ocular structures relevant to the VEGF-induced neovascularization associated with vision loss in wet AMD, and we believe this animal data provides support for the use of bevasiranib in our ongoing pivotal Phase III trial for the treatment of wet AMD," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "It is noteworthy that bevasiranib was distributed to the RPE cells, since we believe that even a fraction of the tissue-associated bevasiranib entering the RPE cell is likely to be effective in specifically suppressing VEGF production."

The Molecular Vision study can be accessed at
http://www.molvis.org/molvis/v14/a119/

"Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes," NS Dejneka, S Wan, OS Bond, DJ Kornbrust, SJ Reich, Molecular Vision, Volume 14, May 28, 2008

Source: OPKO Health, Inc.

[tsylver]

Form 8-K
Current Report
Filed Jun 11, 2008

Stockholders Meeting


http://investor.opko.com/secfiling.cfm?filingID=1144204-08-3…

[cyba]

Antwort auf Beitrag Nr.: 34.286.136 von tsylver am 11.06.08 23:54:13

liest sich nett... am besten gefällt mir "Target Ophthalmic Markets"

[tsylver]

Antwort auf Beitrag Nr.: 34.286.198 von cyba am 12.06.08 00:17:38

nicht schlecht, woll?
Allerdings ist die Zeitschiene zu berücksichtigen.
Aber vielleicht kommt ja ein Investor...

[cyba]

Antwort auf Beitrag Nr.: 34.286.263 von tsylver am 12.06.08 00:54:07

ich hab zeit... und zum flippen ab und an ist OPK wirklich super!

[tsylver]

OPKO Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis
--Novel Agent Has Demonstrated Good Safety and Antiviral Activity in Viral Conjunctivitis--
--Unique Combination of Anti-Infective and Anti-Inflammatory Properties Offers Potential for Broad-Based Ocular Applications--


MIAMI, June 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- OPKO Health, Inc. (AMEX: OPK) today announced that it has acquired exclusive worldwide rights in the field of ophthalmology to a novel small molecule agent in Phase II clinical development for the treatment of viral conjunctivitis and other viral infections. The agent, CTC-96, also known as Doxovir(TM), was developed by Redox Pharmaceutical Corporation. It is a member of a novel drug class that has demonstrated potent anti-viral activity and non-steroidal anti-inflammatory properties with good safety in preclinical and human clinical testing.

"Viral conjunctivitis, popularly known as "pink eye," is among the most common eye disorders, yet patients have no real treatment options for this unsightly, uncomfortable and debilitating condition," said Naveed Shams, M.D., Ph.D., Chief Medical Officer and Senior Vice President of Research and Development of OPKO. "The potent anti-viral activity of CTC-96, its anti-inflammatory properties and its good safety profile make it a potentially ideal candidate for the treatment of viral conjunctivitis."

CTC-96's novel anti-viral mechanism has demonstrated efficacy against multiple viral infections in preclinical studies. CTC-96 should be less susceptible to development of viral resistance than other anti-viral drugs because it disrupts the viral lifecycle by interfering with viral assembly. CTC-96 has anti-inflammatory properties but it is a non-steroidal compound, an important safety advantage for an ocular drug. CTC-96 has successfully completed randomized double-blinded Phase I trials for the treatment of adenovirus keratoconjunctivitis and for the treatment of ocular herpes infection, a leading cause of persistent corneal disease in the developed world.

"This product candidate illustrates our strategy of acquiring agents that address unmet needs in ophthalmology and have a significant commercial upside," said Samuel Reich, OPKO's Executive Vice President of Ophthalmics. "We look forward to initiating Phase II trials assessing CTC-96 for the treatment of viral conjunctivitis in the coming months."

About Viral Conjunctivitis

Adenovirus keratoconjunctivitis is a highly contagious epidemic disease. Viral conjunctivitis is the most common source of acute care visits to eye care professionals in the U.S. Symptoms of viral conjunctivitis include redness, swelling, discharge from the eye, sticking of eyelids, pain or discomfort in the eye and light sensitivity. In 20-50% of cases, corneal opacities accompany the condition and can persist for weeks to months, or even several years. Corticosteroids may be used to limit corneal damage but can have significant side effects and also interfere with viral clearance.

[cyba]

Antwort auf Beitrag Nr.: 34.297.274 von tsylver am 13.06.08 14:04:21

fein

[tsylver]

OPKO Health, Inc. Set to Join Russell 3000 Index



MIAMI, Jun 17, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that it is set to join the broad-market Russell 3000(R) Index when Russell Investment Group reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2008, according to a preliminary membership list posted on Friday, June 13, 2008, on its website at www.russell.com.

Membership in the Russell 3000(R), which remains in place for one year, means OPKO would automatically be included in the small-cap Russell 2000(R) Index, as well as appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.

Dr. Phillip Frost, Chairman of the Board and CEO of OPKO, commented, "We are pleased to be included in the Russell 3000 Index and the opportunity it provides us to increase our visibility within the investment community. We are working diligently to build a world-class organization and OPKO's inclusion in the Russell 3000 is another step in the growth of our company."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. The Russell 3000(R), which serves as the U.S. component to the Russell Global Index, measures the performance of the 3,000 largest U.S. companies based on total market capitalization.

[tsylver]

video] Wallst.net's '3 Minute Press Show' Features Executive Interviews and Highlights Recent Press for the Following: OPK, LBSU, MVTG, TMCI and LUNL
Tuesday June 17, 7:00 am ET


NEW YORK, June 17 /PRNewswire-FirstCall/ -- WallSt.net's 3-Minute Press Show is a daily video program hosted by WallSt.net reporter, Tracee Tolentino.
Shows air Monday through Friday on: http://tv.wallst.net.

WallSt.net's 3-Minute Press Show features in-depth interviews with public company executives on their company and most recent press releases. The show is designed to provide viewers with insight into a company's most recent press release, and its impact on the company's growth.


The following executives were interviewed on today's show:

-- Dr. Phillip Frost, Chairman and CEO of OPKO Health, Inc.
(Amex: OPK - News; http://www.opko.com)
To view this clip in its entirety, visit:
http://tv.wallst.net/r/3-minute-press/michelle/106/514

[cyba]

Antwort auf Beitrag Nr.: 34.324.224 von tsylver am 18.06.08 13:57:55

[tsylver]

Russell 2000 adds 53 health care companies
Monday June 30, 2:16 pm ET
Russell 2000 adds 53 health care companies, 30 companies in sector removed from index


NEW YORK (AP) -- More than 50 companies in the health care sector were added to the Russell 2000 in this year's reconstitution of the small stock index, while 30 companies in the sector were removed from the index.

Accelrys Inc., Acura Pharmaceuticals Inc., Adolor Corp., Almost Family Inc., Alphatec Holdings Inc., Ardea Biosciences Inc., Atrion Corp., Avant Immunotherapeutics, Caliper Life Sciences Inc., Cardiac Science Corp., Cardionet Inc., China Sky One Medical Inc., Clinical Data Inc., Columbia Laboratories Inc., Cougar Biotechnology Inc., Cytori Therapeutics Inc., Depomed Inc., Dexcom Inc., Dyax Corp., Exactech Inc., Five Star Quality Care, Hanger Orthopedic Group Inc., Idera Pharmaceuticals Inc., Immunogen Inc., Inspire Pharmaceuticals Inc. and Iris International Inc. were added to the Russell 2000.

Also joining the Russell 2000 were: Lexicon Pharmaceuticals Inc., Life Sciences Research Inc., Marshall Edwards Inc., Middlebrook Pharmaceuticals Inc., NPS Pharmaceuticals Inc., National Research Corp., Neogen Corp., Novavax Inc., Opko Health Inc., Optimer Pharmaceuticals Inc., Orthovita Inc., Pharmasset Inc., Questcor Pharmaceuticals Inc., Radnet Inc., Repligen Corp., Rexahn Pharmaceuticals Inc., Sangamo Biosciences Inc., Sequenom Inc., Somanetics Corp., Synovis Life Technologies Inc., Targacept Inc., Theravance Inc., Third Wave Technologies., U.S. Physical Therapy Inc., Vision-Sciences Inc. and Vnus Medical Technologies Inc.

PDL Biopharma Inc. moved down to the Russell 2000 from the large-cap Russell 1000.

The following health care companies were removed from the Russell 2000: Altus Pharmaceuticals Inc., American Dental Partners Inc., Animal Health International Inc., Aspect Medical Systems Inc., Bionovo Inc., Cutera Inc., Cytrx Corp., Genvec Inc., Hythiam Inc., Keryx Biopharmaceuticals inc., LCA-Vision Inc., MDRNA Inc., Minrad International Inc., Neurogen Corp., Northstar Neuroscience Inc., Novacea Inc., Penwest Pharmaceuticals Co., Poniard Pharmaceuticals Inc., Santarus Inc., Somaxon Pharmaceuticals Inc., Sonic Innovations Inc., Supergen Inc., Telik Inc., Trubion Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc.

Biomarin Pharmaceutical, Hologic Inc., Illumina Inc., Inverness Medical Innovations Inc. and Perrigo Co., moved up to the Russell 1000, and were removed from the Russell 2000.

Tacoma, Wash.-based Russell Investments realigns the Russell 3000 index once per year, tracking what it maintains is 99 percent of the U.S. equity market. That index is then broken down to 26 smaller indexes, including the widely watched Russell 2000 index of small capitalization stocks.

The makeup of the Russell indexes for the next 12 months was finalized after the closing bell Friday.

[cyba]

hab heute ordentlich gekauft, denke nicht das die noch viel tiefer fallen wird...

[tsylver]

Antwort auf Beitrag Nr.: 34.431.990 von cyba am 03.07.08 16:32:02

was auch immer Du unter ordentlich verstehst
das Ding ist vom ath auf rund 25% zurückgegangen...
Doc Frost sammelt aber auch weiterhin fleissig ein.
Auf jedenfall ist viel Potenzial nach oben.

Viel Glück! (ich bin schon länger dabei)

[cyba]

Antwort auf Beitrag Nr.: 34.433.528 von tsylver am 03.07.08 18:49:49

jo ich weiss das du schon länger dabei bist... ich hab jetzt wieder soviele stücke wie damals als der triple reverse merger anlag und ich in der spitze 300% im plus war (da hiess sie ja noch eXegenic)

heute war kurz nach meinem kauf auch wieder ein fetter kauf der bis zu 1.41 hochging, denke doc frost hat wieder zugeschlagen

ist ein langfristiges invest für mich, wobei ich natürlich weiter versuche mit einigen stücken zu flippen um so mehr shares zu bekommen

[tsylver]

Investors Led by The Frost Group Agree to Make $15 Million Investment in OPKO Health


MIAMI, Aug 08, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX: OPK) today announced that a group of investors led by members of The Frost Group, a private investment group controlled by Dr. Phillip Frost, M.D., Chairman and CEO of OPKO, have agreed to make a $15 million investment in the Company. Under the terms of the investment, OPKO will issue 13,513,514 shares of the Company's common stock, at $1.11 per share, representing a 40% discount to the five-day average trading price of the stock on the American Stock Exchange. The shares issued in the investment will be restricted securities, subject to a two year lockup, and no registration rights have been granted. The Frost Group also includes Dr. Jane Hsiao, Vice Chairman and Chief Technical Officer of OPKO, Mr. Steven D. Rubin, the Company's Executive Vice President-Administration, and Dr. Rao Uppaluri, the Company's Chief Financial Officer.

"This financing transaction provides the Company with additional financial resources to support bringing the Company's projects and pipeline of novel drugs and ophthalmic products to market," said Phillip Frost, M.D., Chairman and CEO. "We continue to believe OPKO has a strong development pipeline and support the Company's efforts in bringing its products to the market."

The closing of the transaction will occur approximately twenty (20) days after the mailing of an information statement to stockholders, which the Company currently anticipates will be on or around September 10, 2008. The proceeds from the investment will be used to fund research and development efforts, including the ongoing Phase III trial for Bevasiranib and for general working capital.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase III clinical trials.

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the gene silencing agent bevasiranib, is in Phase III trials after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits of bevasiranib, our ability to establish OPKO's leadership position, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, the anticipated closing date for the investment, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

SOURCE: OPKO Health, Inc.

OPKO Health, Inc., Miami
Steven D. Rubin, 305-575-6000

[kulo133]

hey,
würde gerne in opko health investieren möchte aber vorher noch einige infos einholen ob es sich jetzt schon lohnt????

[cyba]

Antwort auf Beitrag Nr.: 34.810.731 von kulo133 am 22.08.08 13:51:55

gute frage, momentan flipp ich OPK nur...
ist halt noch ziemlich im anfangsstadium alles von daher für ein echtes long investment m.E. zu früh von daher flippen und so free shares zusammentraden

[tsylver]

OPKO Health to Present at UBS 2008 Global Life Sciences Conference
Wednesday September 17, 9:00 am ET


MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (AMEX:OPK - News) today announced that senior management will present at the UBS 2008 Global Life Sciences Conference on Tuesday, September 23, 2008 at 1:00 PM EDT. The conference will be held at the Grand Hyatt New York in New York City.


OPKO senior management will provide a review of recent corporate developments.

The audio portion of the company’s presentation will be webcast live. To access the audio webcast go to the OPKO Health, Inc. website at www.opko.com and click on the icon for the presentation. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation.

[tsylver]

OPKO Acquires Worldwide Ophthalmic Rights to Teva's Budesonide for Inflammatory and Allergic Ocular Conditions

Offers Potential for Broad Spectrum Ocular Use


MIAMI, Oct 02, 2008 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX:OPK) today announced that it has acquired exclusive worldwide rights from Teva Pharmaceuticals Industries Ltd. (TEVA) to Teva's proprietary formulation of budesonide for the treatment of various inflammatory and allergic conditions of the eye. Teva's proprietary budesonide product is currently marketed in Italy under the tradename XAVIN for the treatment of asthma.

Budesonide is a corticosteroid which has been used for more than 20 years for the treatment of multiple respiratory indications, including asthma, hay fever and other allergies, with demonstrated safety and efficacy.

"We believe that this budesonide formulation can be used for a broad range of ophthalmic indications and has the potential to be a best in class product," said Naveed Shams, M.D., OPKO's Chief Medical Officer and Senior Vice President, Research and Development. "This acquisition is consistent with our strategy of acquiring agents that have a superior risk-benefit profile with significant commercial promise. We look forward to the development of this product in an expeditious and cost-efficient manner."

"Acquiring rights to this late stage product reflects our strategy of proactively seeking new opportunities to help fuel growth at OPKO," said Phillip Frost, M.D., Chairman and CEO of OPKO Health. "This compound has demonstrated safety and the potential to reach the market relatively quickly. It addresses a significant commercial opportunity for OPKO."

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at www.opko.com.

[tsylver]

OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD




MIAMI, Dec 04, 2008 (BUSINESS WIRE) --

OPKO Health, Inc. (AMEX OPK) announced today that it has completed enrollment in the Company's Phase III clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD). The multi-national study has enrolled more than 330 patients and is designed to assess the efficacy and safety of bevasiranib administered every 8 or 12 weeks in preventing vision loss due to wet AMD.

Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF). VEGF is believed to be largely responsible for the vision loss from wet AMD and bevasiranib is the first drug based on the Nobel Prize-winning RNA interference (RNAi) concept to be in Phase III clinical trials.

"This first-ever Phase III trial of an agent based on RNAi technology is a milestone in the field of RNAi," said Phillip Frost, M.D., Chairman and CEO of OPKO Health. "With the completion of enrollment, we are one step closer to our goal of submitting a New Drug Application to regulatory agencies worldwide."

About Wet AMD

Wet age-related macular degeneration is a leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis(R), slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility.

For more information about the COBALT bevasiranib clinical study, please visit www.opko.com/clinicaltrials.

About OPKO Health, Inc.

[tsylver]

OPKO Health Initiates Clinical Trial of the Aquashunt(TM) to Treat Glaucoma

MIAMI, Jan 22, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (AMEX OPK) announced today that it has begun treating patients in a clinical trial of its Aquashunt(TM), a device for the treatment of refractory open angle glaucoma. The study, at two academic departments of ophthalmology, is designed to assess the safety and efficacy of the Aquashunt(TM) and will enroll up to 20 patients with significantly impaired visual acuity.

The Aquashunt(TM) is a novel device designed to lower intraocular pressure by allowing excess fluid in the eye to exit more naturally than occurs with presently available devices.

"We are pleased by the simplicity of the surgical procedure for the device and by the early results in the first human trials," commented Bruce Shields, M.D., Professor of Ophthalmology at Yale University and designer of the Aquashunt(TM). "These early results provide further validation of our optimism for the future of the Aquashunt(TM), and we look forward to completing our clinical trials and bringing this product to market."

About Glaucoma

Glaucoma occurs when fluid accumulating in the eye raises the intraocular pressure and causes the optic nerve to degenerate, potentially leading to irreversible vision loss. Glaucoma is increasing in prevalence as the population ages, currently affecting an estimated 2.4 million people in the U.S. and about 60 million people worldwide.

It is the leading cause of bilateral, irreversible blindness.

[tsylver]

OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System
Friday January 23, 2009, 9:13 am EST
Yahoo! Buzz Print Related: Opko Health, Inc.
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Alternext US: OPK) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to begin marketing in the United States its Spectral OCT SLO Combination Imaging System. Currently marketed internationally by the Company’s subsidiary, OPKO Instrumentation, LLC, the Spectral OCT SLO is the product of more than a decade of innovation in the field of combination imaging. High-resolution images are produced with inner retinal choroid and vitreous detail that allow for improved monitoring of ophthalmic disease progression or regression.

"We are pleased to receive 510(k) clearance for the OPKO Spectral OCT SLO Combination Imaging System,” said Jane H. Hsiao, Ph.D., Vice Chairman and Chief Technical Officer of OPKO Health, and President of OPKO Instrumentation. “We believe that the high image quality produced by our Spectral OCT SLO and its versatile user-friendly interface offer the clinician a valuable tool for the detection and visualization of ocular pathologies. In addition, we recently hosted a FDA audit at our facility in Toronto, Canada where we manufacture our Spectral OCT SLO and ultrasound products and are pleased to announce it was accepted without any citation of deficiency after the inspection.”

About the Spectral OCT SLO

The Spectral OCT SLO is a non-contact, high-resolution non-invasive tomographic and confocal imaging device indicated for in vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of posterior ocular structures including: retina, macula, retina nerve fiber layer and optic disk. It is used as a diagnostic device to aid in the detection and management of ocular diseases affecting the posterior segment of the eye. In addition, the system can image the cornea, sclera and conjunctiva by changing the focal position.

[tsylver]

OPKO To Present Data on Next Generation Anti-Angiogenic VEGF165b-Sparing siRNA at Association for Research and Vision in Ophthalmology (ARVO 2009) Meeting
Tuesday February 10, 2009, 12:15 pm EST
Yahoo! Buzz Print Related: Opko Health, Inc.
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Alternext US: OPK) today announced that it will present initial data on the characterization of its next generation anti-VEGF siRNA molecules. These new proprietary siRNA’s are designed to inhibit the angiogenic Vascular Endothelial Growth Factor A165 (VEGFA165 isoform) but spare the anti-angiogenic VEGFA165b isoform.

VEGFA165 is known to play a critical role in diseases of the eye where the underlying cause of the problem is abnormal growth of blood vessels, such as in wet Age-related Macular Degeneration. To the contrary, data show that VEGFA165b is an inhibitor of abnormal vessel growth.

"We are pleased to present data regarding our new siRNA molecules that spare the so-called VEGF165b at the upcoming ARVO 2009 meeting in Fort Lauderdale,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health. “We believe that these new proprietary molecules have the potential to significantly improve clinical outcomes in patients with ocular neovascularization.” Dr. Frost further noted that the synthesis of these new siRNA’s adds significant breadth to OPKO’s already substantial intellectual property portfolio in the RNAi space.

[tsylver]

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2009 OPKO Health, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware 000-26648 75-2402409
(State or other
jurisdiction of
incorporation) (Commission
File Number) (IRS Employer
Identification No.)

4400 Biscayne Blvd
Suite 1180
Miami, Florida 33137
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: [phone]

(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


ITEM 1.01. Entry into a Material Definitive Agreement.
Pursuant to a Stock Purchase Agreement with OPKO Health, Inc. (the “Company”) dated February 23, 2009, Frost Gamma Investments Trust (the “Gamma Trust”), of which Phillip Frost, M.D., the Company’s Chairman and CEO, is the sole trustee, agreed to make a $20 million investment in the Company. Under the terms of the investment, the Company will issue to the Gamma Trust 20,000,000 shares of the Company’s common stock, par value $.01 (the “Shares”), at $1.00 per share, representing an approximately 20% discount to the average closing price of the Company’s common stock on the NYSE Alternext U.S. Exchange immediately preceding the effective date of Audit Committee and stockholder approval of the transaction (the “Investment”). The Shares issued in the Investment will be restricted securities, subject to a two year lockup, and no registration rights have been granted.
The Company’s Audit Committee and stockholders holding a majority of the voting power of the outstanding capital stock of the Company approved the Investment by one or more members of the Frost Group, LLC, a private investment group controlled by Dr. Frost, on February 13, 2009. Stockholder approval was sought in order to comply with applicable rules of the NYSE Alternext U.S. Exchange. Stockholder approval of the Investment was in the form of a written consent of stockholders in lieu of a special meeting in accordance with the relevant sections of the Delaware General Corporation Law. The Company intends to file with the Securities and Exchange Commission and mail to stockholders an Information Statement informing our stockholders of the Investment and the approval of the issuance of the Shares. The Closing of the Investment and the issuance and delivery of the Shares is expected to occur approximately twenty (20) days after the mailing of the Information Statement to stockholders, which we currently anticipate will be on or around March 26, 2009; provided however, that that the Closing of the Investment and issuance and delivery of the Shares is subject to the expiration or termination of any waiting period under the Federal Trade Commission’s Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”) and the rules of the Federal Trade Commission relating to the HSR Act.
In addition to the Gamma Trust, The Frost Group, LLC also includes as its members, Dr. Jane Hsiao, Vice Chairman and Chief Technical Officer of OPKO, Dr. Rao Uppaluri, the Company’s Chief Financial Officer, and Mr. Steven D. Rubin, the Company’s Executive Vice President-Administration and a director. Following the Investment, the Gamma Trust will be deemed to beneficially own in the aggregate approximately 52% of the Company’s common stock.
ITEM 3.02. Unregistered Sales of Equity Shares
The information disclosed under Item 1.01 of this report is incorporated into this Item 3.02 in its entirety. The issuance of the common stock will be exempt from the registration requirements under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, because the transaction does not involve a public offering.
2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By /s/ Rao Uppaluri
Name: Rao Uppaluri
Title: Chief Financial Officer


Date February 24, 2009

[tsylver]

OPKO Health Announces Update on Phase III Clinical Trial of Bevasiranib


MIAMI, Mar 06, 2009 (BUSINESS WIRE) -- OPKO Health, Inc. (NYSE Alternext US: OPK)today announced that, following the recommendation of the Independent Data Monitoring Committee (IDMC), it had decided to terminate its Phase III clinical study of Bevasiranib, a first-in-class siRNA, for the treatment of wet age-related macular degeneration (wet-AMD). Although preliminary data, needing further analysis, show activity of Bevasiranib when used adjunctively with Genentech's Lucentis(R),review of the data by the IDMC indicated that the trial, as structured, was unlikely to meet its primary end point. There were no systemic safety issues identified and local ocular safety was generally unremarkable.

"While we are clearly disappointed with the preliminary results of this fully-enrolled study, the indications of activity are encouraging and we look forward to fully analyzing the data in the coming weeks," said Dr. Phillip Frost, Chairman and CEO of OPKO Health. "We remain committed to the continued development of our siRNA portfolio targeting Vascular Endothelial Growth Factor (VEGF), including our recently announced VEGFA165b sparing siRNA." These new proprietary siRNA's are designed to inhibit the angiogenic Vascular Endothelial Growth Factor A165 (VEGFA165 isoform) but spare the anti-angiogenic VEGFA165b isoform.

VEGFA165 is known to play a critical role in diseases of the eye where the underlying cause of the problem is abnormal growth of blood vessels, such as in wet age-related macular degeneration. To the contrary, data show that VEGFA165b is an inhibitor of abnormal vessel growth.

[kulo133]

hey, gibt es irgendetwas neues was die nächsten tests angeht???